Algert Global LLC Atreca, Inc. Transaction History

Algert Global LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.56 - $3.25 $26,036 - $54,242	-16,690 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.61 - $5.2 $8,790 - $28,392	-5,460 Reduced 24.65%	16,690 $53,000
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $1,549 - $3,396	540 Added 2.5%	22,150 $67,000
Q3 2021 Nov 15, 2021	BUY	$4.91 - $9.07 $16,153 - $29,840	3,290 Added 17.96%	21,610 $135,000
Q2 2021 Aug 13, 2021	SELL	$7.82 - $13.8 $102,989 - $181,746	-13,170 Reduced 41.82%	18,320 $156,000
Q1 2021 May 14, 2021	BUY	$13.0 - $19.34 $23,920 - $35,585	1,840 Added 6.21%	31,490 $483,000
Q4 2020 Feb 12, 2021	BUY	$13.03 - $17.09 $386,339 - $506,718	29,650 New	29,650 $479,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.